Crovalimab is currently in clinical development for patients with paroxysmal nocturnal
haemoglobinuria (PNH). PNH is a rare, acquired, life-threatening disease of the blood. The disease
is characterised by destruction of red blood cells, blood clots, and impaired bone marrow function.
It is a blood condition where blood cells are prone to be attacked by part of the body’s immune
system.
Crovalimab for treatment of paroxysmal nocturnal haemoglobinuria
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Patients-Public_Motifs_Conduction-broadcasting_RGB-scaled_edit1233.jpg)
Crovalimab is currently in clinical development for patients with paroxysmal nocturnal haemoglobinuria (PNH).
Interventions:
Crovalimab
Indications:
Paroxysmal nocturnal haemoglobinuria (PNH)
Therapeutic Areas:
Haematology
Year:
2022